Skip to main content

Table 6 Budget impact analysis results

From: Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology

Year

MS/MSa

IFb

Difference

Screening cost

Treatment cost

Total sum

Screening cost

Treatment cost

Total sum

Screening cost

Total sum

2019

47.36

0.27

47.63

3.68

0.58

4.26

43.68

43.37

2020

47.36

0.65

48.01

3.68

1.40

5.08

43.68

42.94

2021

47.36

1.02

48.38

3.68

2.09

5.77

43.68

42.61

2022

47.36

1.44

48.80

3.68

3.02

6.70

43.68

42.10

2023

47.36

1.77

49.13

3.68

3.74

7.42

43.68

41.71

2024

47.36

2.15

49.51

3.68

4.44

8.12

43.68

41.39

2025

47.36

2.56

49.92

3.68

5.36

9.04

43.68

40.88

2026

47.36

2.94

50.30

3.68

6.21

9.89

43.68

40.41

2027

47.36

3.27

50.63

3.68

6.90

10.58

43.68

40.05

2028

47.36

3.60

50.96

3.68

7.74

11.42

43.68

39.54

Total sum

473.60

19.66

493.26

36.80

41.47

78.27

436.80

415.00

  1. aMS/MS Tandem mass spectrometry;
  2. bIF immunofluorescence